Future directions in antiarrhythmic drug therapy for atrial fibrillation

Future Cardiology

Volumn 2, Issue 5, 2006, Pages 545-553

  Musco, Simone ^a   Seltzer, Jonathan ^a   Kowey, Peter R ^b  

^a Main Line Heart Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Azimilide; Dronedarone; Tedisamil

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 6 N CYCLOHEXYL 2' O METHYLADENOSINE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATI 2001; ATI 2042; AZD 7009; AZIMILIDE; BENZOFURAN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; FLECAINIDE; IBUTILIDE; NEW DRUG; PROPAFENONE; QUINIDINE; RS 100302; RSD 1235; SEROTONIN ANTAGONIST; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SSR 149744C; TECADENOSON; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; BRONCHOSPASM; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG TOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; THYROID DISEASE; TORSADE DES POINTES; UNITED STATES;

EID: 33749566555     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.5.545     Document Type: Review

References (65)

1. Benjamin EJ, Wolf PA, D'Agostino RB et al.: Impact of atrial fibrillation on the risk of death. The Framingham heart study. Circulation 98, 946-952 (1998).
2. Ho KK, Pinsky JL, Kannel WB et al.: The epidemiology of heart failure: the Framingham study. J. Am. Coll. Cardiol. 22, A6-A13 (1993).
3. Haissaguerre M, Jais P, Shah DC et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 349, 659-666 (1998)
4. Earley MJ, Schilling RJ: Catheter and surgical ablation of atrial fibrillation. Heart 92(2), 266-274 (2006).
5. Goldstein RN, Stambler BS: New antiarrhythmic drugs for prevention of atrial fibrillation. Cardiovasc. Dis. 48(3), 193-208 (2005).
6. Pecini R, Elming H, Pedersen OD et al.: New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin. Emerg. Drugs 10(2), 311-322 (2005).
7. Echt DS, Liebson PR, Mitchell LB et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324(12), 781-788 (1991)
8. Auer J, Berent R, Eber B: Amiodarone in the prevention and treatment of arrhythmia. Curr. Opin. Investig. Drugs 3(7), 1037-1044 (2002).
9. Sun W, Sarma JS, Singh BN: Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100(22), 2276-2281 (1999).
10. Sun W, Sarma JS, Singh BN: Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J. Cardiovasc. Pharmacol. 39(5), 677-684 (2002).
11. Hohnloser SH: EURIDIS and ADONIS: maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter Presented at: the European Society of Cardiology Congress: Munich, Germany, 28 August-1 September 2004.
12. Davy JM on behalf of the ERATO Investigators: Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation american heart association. Scientific Session, session number APS.52.4, presentation 2737 at: American Heart Association Scientific Sessions, November 15 (2005).
13. Raatikainen MJ, Napolitano CA, Druzgala P, Dennis DM: Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J. Pharmacol. Exp. Ther. 277(3), 1454-1463 (1996).
14. Raatikainen MJ, Morey TE, Druzgala P, Milner P, Gonzalez MD, Dennis DM: Potent and reversible effects of ATI-2001 on atrial and atrioventricular nodal electrophysiological properties in guinea pig isolated perfused heart. J. Pharmacol. Exp. Ther. 295(2), 779-785 (2000).
15. Juhasz A, Bodor N: Cardiovascular studies on different classes of soft drugs. Pharmazie 55(3), 228-238 (2000).
16. Morey TE, Seubert CN, Raatikainen MJ et al.: Structure - activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J. Pharmacol. Exp. Ther. 297(1), 260-266 (2001).
17. Pritchett EL, Page RL, Connolly SJ et al.: Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J. Am. Coll. Cardiol. 36(3), 794-802 (2000).
18. Roy D, Talajic M, Dorian P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med. 342, 913-920 (2000).
19. Naccarelli GV, Wolbrette DL, Kahn M et al.: Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am. J. Cardiol. 91, D15-D26 (2003).
20. Camm AJ, Pratt CM, Schwartz PJ et al.: AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109(8), 990-996 (2004).
21. Pratt CM, Singh SN, Al-Khalidi HR et al.: ALIVE Investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J. Am. Coll. Cardiol. 43(7), 1211-1216 (2004).
22. Pritchett EL, Kowey P, Connolly S et al.: Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am. Heart J. 151(5), 1043-1049 (2006).
23. Page RL: A-STAR and A-COMET Trials (Azimilide in atrial fibrillation) Europace 3, A2 (2002) (Abstract).
24. Baskin EP, Lynch JJ: Differential atrial versus ventricular activities of class III potassium channel blockers. J. Pharmacol. Exp. Ther. 285, 135-142 (1998).
25. Hohnloser SH, Dorian P, Straub M et al.: Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. 44(1), 99-104 (2004).
26. Beatch GN, Shinagawa K, Johnson B et al.: RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria (abstract). Pacing Clin. Electrophysiol. 25, 698 (2002).
27. Beatch GN, Lin S-P, Hesketh JC et al.: Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug (abstract). Circulation 108(Suppl. IV), IV85 (2003).
28. Ezrin AM, Grant SM, Bell G et al.: A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers (abstract). Pharmacologist 44 (Suppl. 1), A15 (2002).
29. Roy D, Rowe BH, Stiell IG et al: CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44(12), 2355-2361 (2004).
30. +-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc. Res. 60(2), 298-306 (2003).
31. Blaauw Y, Gogelein H, Tieleman RG et al.: "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110(13), 1717-1724 (2004).
32. Goldstein RN, Khrestian C, Carlsson L, Waldo AL: Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol. 15(12), 1444-1450 (2004).
33. Wu Y, Carlsson L, Liu T, Kowey PR, Yan GX: Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J. Cardiovasc. Electrophysiol. 16(8), 898-904 (2005).
34. Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ: A 5-HT receptor in human atrium. Br. J. Pharmacol. 100, 879-885 (1990).
35. 2+-channel, β-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res. Cardiol. 96(1), 82-90 (2001).
36. Rahme MM, Cotter B, Leistad E et al.: Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 100(19), 2010-2017 (1999).
37. Ellenbogen KA O'Neill G, Prystowsky EN et al.: Randomized, double-blind, placebo-controlled study of intravenous CVT-510 in patients with PSVT undergoing an electrophysiologic study. Circulation 111(24), 3202-3208 (2005).
38. Piot O, Chauvel C, Lazarus A et al.: Effects of a selective A1-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation. Pacing Clin. Electrophysiol. 21(11), 2459-2464 (1998).
39. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100(4), 376-380 (1999).
40. Vermes E, Tardif JC, Bourassa MG et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23), 2926-2931 (2003).
41. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC: Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J. Am. Coll. Cardiol. 44(1), 159-164 (2004).
42. Goette A, Staack T, Rocken C et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol. 35(6), 1669-1677 (2000).
43. Goette A, Arndt M, Rocken C et al.: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101 (23), 2678-2681 (2000).
44. Ueng KC, Tsai TP, Yu WC et al: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur. Heart J. 24(23), 2090-2098 (2003).
45. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101(22), 2612-2617 (2000).
46. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41(12), 2197-2204 (2003).
47. Maggioni AP, Latini R, Carson PE et al.: Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 149(3), 548-557 (2005).
48. Wachtell K, Lehto M, Gerdts E et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 45(5), 712-719 (2005).
49. Fogari R, Mugellini A, Destro M et al.: Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J. Cardiovasc. Pharmacol. 47(1), 46-50 (2006).
50. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106(3), 331-336 (2002).
51. Disertori M, Latini R, Maggioni AP et al.: Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J. Cardiovasc. Med. (Hagerstown) 7 (1), 29-38 (2006).
52. Caballero R, Moreno I, Gonzalez T et al.: Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107(6), 889-895 (2003).
53. Gomez R, Nunez L, Caballero R, Vaquero M, Tamargo J, Delpon E: Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. Br. J. Pharmacol. 146(1), 146-161 (2005).
54. Goldstein RN, Kyungmoo R, Van Wagoner DR, Stambler B, Waldo A: Prevention of postoperative atrial fibrillation and flutter using steroids (abstract). PACE 26, 1068 (2003).
55. Kumagai K, Nakashima H, Saku K: The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc. Res. 62(1), 105-111 (2004).
56. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S: Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110(16), 2313-2319 (2004).
57. Siu CW, Lau CP, Tse HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. 92(11), 1343-1345 (2003).
58. Young-Xu Y, Jabbour S, Goldberg R et al.: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. 92(12), 1379-1383 (2003).
59. Tveit A, Grundtvig M, Gundersen T et al: Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. 93(6), 780-782 (2004).
60. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT: Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128(5), 3421-3427 (2005).
61. Marin F, Pascual DA, Roldan V et al.: Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol. 97(1), 55-60 (2006).
62. Ninio DM, Murphy KJ, Howe PR, Saint DA: Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J. Cardiovasc. Electrophysiol. 16(11), 1189-1194 (2005).
63. Biscione F, Totteri A, De Vita A, Lo Bianco F, Altamura G: Effect of omega-3 fatty acids on the prevention of atrial arrhythmias. Ital. Heart. J. Suppl. 6(1), 53-59 (2005).
64. Calo L, Bianconi L, Colivicchi F et al.: N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized. controlled trial. J. Am. Coll. Cardiol. 45(10), 1723-1728 (2005).
65. Brouwer IA, Heeringa J, Geleijnse JM et al: Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am. Heart J. 151(4), 857-862 (2006).